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Background: The GTP-binding protein, GDs, 
facilitates myometrial quiescence during 
pregnancy. 
Results: TNF overcomes Trichostatin A 
(TSA)-induced myometrial relaxation. This is 
due to changes in levels of CBP and acetylated 
H4K8 within the GDs promoter. 
Conclusions: Promoter acetylation is 
important in governing expression of GDs. 
Significance: TSA-induced myometrial 
relaxation can be overcome by TNF through 
repression of GDs promoter activity. 
 
Summary 
The onset of parturition is associated with a 
number of pro-inflammatory mediators 
which are themselves regulated by the 
Nuclear Factor kappa B (NF-NB) family of 
transcription factors. In this context we 
previously reported that the RelA NF-NB 
subunit represses transcription and mRNA 
expression of the pro-quiescent GDs
 
gene in 
human myometrial cells following 
stimulation with the pro-inflammatory 
cytokine TNF. In this present study we 
initially defined the functional consequence 
of this on myometrial contractility. Here we 
show that, contrary to our initial 
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expectations, TNF did not induce 
myometrial contractility but did inhibit the 
relaxation produced by the HDAC 
inhibitor, TSA; an effect which was, in turn, 
abolished by the NF-NB inhibitor, QNZ. 
This result suggested a role for TNFin 
regulating GDs expression via activating 
NF-NB and modifying histone acetylation 
associated with the promoter region of the 
gene. In this context we show that the -837 
to -618 region of the endogenous GDs 
promoter is occupied by CREB, Egr-1 and 
Sp1 transcription factors and that CBP 
transcriptional complexes form within this 
region where it induces histone acetylation 
resulting in increased GDs expression. TNF, 
acting via NF-NB, did not change the levels 
of CREB, Sp1 or Egr-1 binding to the GDs 
promoter but it induced a significant 
reduction in the level of CBP. This was 
associated with increased levels of HDAC-1 
and, surprisingly, an increase in H4K8 
acetylation. The latter is discussed herein. 
 
Introduction 
During pregnancy the uterus adopts a relative 
state of myometrial smooth muscle inactivity 
termed quiescence.  At the onset of labour, the 
quiescent state is lost and a series of powerful 
myometrial contractions occur that act to expel 
the infant. In the developed world, premature 
birth complicates 6-10% of pregnancies (1). 
Significantly, the incidence of birth before 28 
weeks gestation (severely preterm) is 
increasing (2, 3) with those infants having 
elevated risks of major long-term mental and 
physical handicap (4). 
 
There is growing evidence indicating that in 
the human myometrium, the cessation of 
uterine quiescence (myometrial relaxation) and 
the onset of both normal and preterm labour 
are associated with a number of pro-
inflammatory factors and cytokines, including 
TNF, IL1-E, IL-8 and COX-2, which are 
regulated by a family of transcription factors 
collectively referred to as Nuclear Factor 
kappaB (NF-NB) (5-22; reviewed in 23, 24). 
 
While it is accepted that NF-ț% LV
predominantly considered an activator of gene 
expression, a body of evidence exists that also 
supports the thesis that NF-ț% FDQ DFW DV D 
repressor of transcription. It can do this 
directly by binding to DNA and recruiting 
inhibitory factors such as histone-deacetylase 
proteins to the promoter (25-27) or through 
interaction with other transcription factors 
such as Egr-1, c-Myc and Sp1 (28-31; 
reviewed in 32). Of significance, however, is 
that NF-ț%FDQUHSUHVVWUDQVFULSWLRQRIFHUWDLQ
genes via in-direct non-DNA binding 
mechanisms that involve competing for 
cellular co-activators of transcription such as 
CBP and p300 (33, 34). Such factors are 
recognised as enzymes capable of making 
chromatin more accessible to the transcription 
machinery through induction of histone 
acetylation indicative of epigenetic changes. 
Consequently, removal of these transcription 
factors from a given promoter by NF-NB may 
favour promoter histone deacetylation and 
subsequent transcriptional repression. 
 
The importance of epigenetic mechanisms in 
the establishment, regulation and maintenance 
of transcriptional activation or repression is 
well documented (35, 36). Chromatin is the 
term given to DNA when it assumes a highly 
ordered, structured complex within the 
nucleus. The fundamental unit of chromatin is 
the nucleosome consisting of 150 bp of DNA 
wrapped around a core histone octamer (two 
each of H2A, H2B, H3, and H4; 37). 
Importantly, DNA-mediated processes, 
including transcription, must occur within the 
architectural confines of the nucleosome. In 
general, chromatin is highly repressive to 
events such as transcription because the 
folding of the DNA results in the steric 
blockade of the template greatly reducing its 
accessibility by the relevant enzymes and 
ancillary factors. To circumvent this problem, 
eukaryotic cells have evolved in a manner that 
allows the chromatin to be carefully 
manipulated thereby permitting controlled 
access to DNA at the appropriate temporal 
junction.  Indeed, eukaryotes have developed 
multiple mechanisms to finely tune chromatin 
structure: a principle approach involving post-
translational modification of histones 
including acetylation (38), methylation (39) 
and phosphorylation (40), all of which are laid 
down in a dynamic fashion. 
 
The full repertoire of molecular factors that 
perpetuate myometrial quiescence remains 
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unknown. It is clear, however, that 
components of the cAMP/protein kinase A 
(PKA) pathway are differentially expressed in 
the human myometrium during pregnancy (41-
47): central to this is the GTP-binding protein, 
*ĮV. Indeed, signalling through GDs is thought 
to facilitate promotion of myometrial 
quiescence and GDs protein levels have been 
shown to be reduced at the onset of labour (41, 
42).  There are, however, only a limited 
number of reports describing the 
transcriptional control of the GDs gene. The 
GDs promoter itself is located on chromosome 
20, is a highly GC-rich segment of DNA and 
therefore contains many binding sites for 
transcription factors which bind GC-
containing DNA sequences including those for 
CREB, Egr and Sp families (48-51). Our 
previous studies have suggested that the 
promoter region of the GDs gene is regulated 
by Sp-like transcription factors that require 
phosphorylation by PKA (44-46). Moreover, 
we have demonstrated that TNF-induced 
activation of NF-ț% OHG WR WKH UHSUHVVLRQ RI
the GDs promoter in a manner that utilised 
competition for the co-activator and histone 
acetyltransferase, CBP (22). In our view, since 
levels of CBP are elevated in pregnant human 
myometrium but decline in labouring samples 
(52), this suggests that epigenetic control of 
quiescence may also be important in human 
parturition. 
 
In this study, we demonstrated that TNF 
significantly reduced Trichostatin A (TSA)-
induced myometrial relaxation. Moreover, the 
NF-NB inhibitor, N4-[2-(4-
phenoxyphenyl)ethyl]-4,6-quinazolinediamine, 
(QNZ), prevented the effects of TNF. Utilising 
the chromatin immunoprecipitation (ChIP) 
assay, we show that the native GDs promoter 
is occupied by CREB, Egr-1, Sp1 and CBP; 
moreover, both promoter occupancy by CBP 
and acetylation status of histone H4K8 were 
subsequently modified in the presence of TNF 
and the histone deacetylase inhibitor, TSA. We 
discuss the implications of these findings. 
 
Materials and Methods: 
Selection of Patients and Tissue Collection 
Women were recruited from the Department of 
Obstetrics and Gynaecology at the Jessop 
Wing, Sheffield Teaching Hospitals NHS 
Foundation Trust, Sheffield South Yorkshire 
U.K. This study received approval from the 
Rotherham Local Research Ethics Committee 
(REC Reference No. 05/Q2306/22). All 
patients gave informed, written consent. 
Lower uterine segment myometrial samples 
were obtained from healthy women 
undergoing elective Caesarean section at term 
(n = 45, age 16-43, gestation 37-40 weeks) as 
described previously (21, 22). Myometrial 
smooth muscle cell cultures were then 
subsequently generated as detailed in Phaneuf 
et al. (43). 
 
Cell Culture, Transient Transfections, 
Plasmids and Luciferase Assays 
Transient transfection of primary human 
myometrial cells was performed using the LT-
1 reagent from Miras (Geneflow, Staffordshire 
UK) as described by Chapman et al. 2005 
(22). The GDs-luciferase reporter (GDs-luc) 
has been described previously (45). The 3x-
NB-ConA-luciferase (3x-NB-ConA-Luc) and 
enh-ConA-luciferase ('NB-ConA-Luc) vectors 
were the generous gift of Prof. Ron Hay 
(University of Dundee, UK) and the 
construction of these has been reported in 
detail (53). The RcRSV-HA-CBP expression 
plasmid was supplied by Dr. Paul Hurd, 
(Queen Mary University of London, UK) but 
was originally generated in the Goodman 
laboratory (Vollum Institute, Portland, 
Oregon) and its construction has been 
described elsewhere (54). The pcDNA-
HDAC-1 vector was the gift of Prof. Bradley 
Bernstein (Department of Pathology, 
Massachusetts General Hospital, Harvard 
Medical School) and its construction has been 
described previously (55). For each 
transfection, 200 ng of luciferase reporter was 
used. Twenty-four hours after transfection, 
cells were then stimulated for a further 24 
hours with 10 ng/ml TNF. For experiments 
investigating the role of CBP, 200 ng RcRSV-
HA-CBP or 200 ng RcRSV-NRC-MCS were 
employed. Transfections using HDAC-1 
utilised 0.5 Pg, 1.0 Pg and 1.5 Pg pcDNA-
HDAC-1, or 0.5 Pg, 1.0 Pg and 1.5 Pg 
pcDNA3 to normalise the amount of DNA. 
Luciferase assays were performed three times 
in triplicate as previously described (22) and 
data collected using a Berthold Sirius 
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luminometer (Geneflow Ltd. Staffordshire, 
UK).  
 
Immunofluorescence 
Myometrial cells were cultured in a 24-well 
plate and upon reaching 80% confluence were 
stimulated with 10 ng/ml TNF for 24 hours. 
The cells were washed in PBS and fixed in 1% 
(v/v) formaldehyde overnight at 4°C. Cells 
were washed in PBS 3 times for 5 minutes on 
a rocking platform and permeablised with PBS 
containing 1% (w/v) BSA and 0.1% (v/v) 
Triton X-100 with 3, 5 minute washes. After 
washing again in PBS, RelA antiserum (Santa 
Cruz Biotechnology Inc. sc-372) was added to 
each well at a dilution of 1:100 (in PBS 
containing 1% (w/v) BSA) for 2 hours at 
37°C. The antibody was removed with three 5-
minute washes in PBS and the goat anti-rabbit 
IgG secondary antibody was added to the 
wells at a dilution of 1:200 (in PBS, 1% (w/v) 
BSA) for 1 hour at 37°C. The unbound 
antibody was washed with three, five minute 
PBS washes and the nuclear counter-stain 
DAPI added to the wells at a 1:20 dilution in 
PBS.  
 
Chromatin Immunoprecipitation (ChIP) 
Assay  
The ChIP assay was performed using the 
Magna-ChIP ChIP assay kit provided by 
Millipore (#17-611) following the 
PDQXIDFWXUHU¶VJXLGHOLQHV(VVHQWLDOO\IRXU7-
75 flasks of primary myocytes were grown to 
100% confluence. Two of these flasks were 
then stimulated with 10 ng/ml TNF for 24 
hours. Cells were then fixed for 10 minutes 
using 37.5% formaldehyde added directly to 
the media. This reaction was subsequently 
quenched by adding 2 ml 1M glycine made up 
in water. Finally, media was removed and cells 
washed twice in ice cold PBS (pH 7.4) 
supplemented with protease inhibitor cocktail 
(Millipore). Cells were removed from each 
flask in the PBS:protease inhibitor cocktail 
using a cell scraper. Appropriate samples were 
then pooled into control or stimulated groups 
and the cell suspension clarified by 
centrifugation at 4°C at 800g for five minutes. 
 
The cell pellet was re-suspended in 500 Pl 
Magna-ChIP lysis buffer supplemented with 
protease inhibitor cocktail.  Essentially a two-
step lysis was undertaken to reduce non-
specific chromatin:IgG interactions. In the first 
lysis step, cells were opened and nuclei 
obtained; cells were then incubated in lysis 
buffer on ice for 15 minutes and vortexed 
briefly every five minutes. This suspension 
was clarified by centrifugation at 800g for five 
minutes at 4°C. For the second lysis step, 
which opened the nuclei, the supernatant was 
discarded and the pellet re-suspended in 500 Pl 
of Magna-ChIP nuclear lysis buffer and the 
sample subjected to ultrasonic cavitation on 
high power for three 10 second exposures in 
order to lyse the nuclei and fragment the 
chromatin. Chromatin fragments with an 
average size of ~500bp were obtained. 
 
Immunoprecipitation of Chromatin-bound 
Complexes 
The fragmented chromatin was separated in to 
50µl aliquots (approximately 1x106 cells) and 
then diluted in 450 ȝORI0DJQD-ChIP dilution 
buffer. To each sample, 5 µg of 
immunoprecipitating antibody was added. 
Antisera used were anti-RelA C-terminal 
antibody (Santa Cruz Biotechnology Inc. sc-
372), anti-Sp1 (Santa Cruz Biotechnology Inc. 
sc-), anti-CREB (Cell Signalling Technology; 
#9192), anti-acetylated histone-H3 (H3K9; 
Millipore; #06-599) and anti-acetylated 
histone H4 (H4K8; Cell Signalling 
Technologies; #2594), CBP and Egr-1 (Santa 
Cruz Biotechnology Inc. sc-369 and sc-588 
respectively) and non-specific rabbit IgG 
(Abcam; #ab46450). To this a 20 µl bed 
volume of pre-prepared Dyna-beads 
(Invitrogen) pre-DGVRUEHG ZLWK  ȝJPO
sonicated salmon sperm DNA and 1 mg/ml 
BSA in TE buffer were added. The 
immunoprecipitation reactions were carried 
out overnight at 4°C with constant, gentle 
agitation. After this period, 
immunoprecipitated complexes were 
recovered with a magnet and the beads washed 
to remove non-specific binding using 
alternative high salt:low salt and LiCl washes 
LQ DFFRUGDQFH ZLWK WKH PDQXIDFWXUHU¶V
instructions. Transcription factor-bound DNA 
was then eluted and purified as detailed in the 
Magna-ChIP protocol and stored at -20°C. 
 
PCR of Immunoprecipitated DNA 
PCR on the immunoprecipitated DNA was 
carried out using primers flanking the NB sites 
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within the INBD SURPRWHU VHQVH ¶-
GACGACCCCAATTCAAATCG-¶ DQGDQWL-
VHQVH ¶-TCAGGCTCGGGGAATTTCC-¶
as a positive control for the ChIP assay giving 
a product size of ~300bp (22). As a positive 
control for promoter occupancy by CBP, PCR 
on the immunoprecipitated DNA was also 
carried out using primers flanking the CXCL-9 
promoter (56). The primer sequences used 
were CXCXL- VHQVH ¶-
TTCCACATCCAGGTAGCAACTTTG-¶
and CXCL- DQWLVHQVH ¶-
TGTTGGAGTGAAGTCCGAGAATGT-¶
These primers gave the expected product size 
of 86bp. Reactions conditions for both controls 
were those originally described in Saccani et 
al. (57) and are given here: one cycle of 
denaturation at 94qC 3 minutes, 36 cycles of 
94qC 45 seconds, 60qC for 1 minute and 72qC 
for 1 minute followed by a final elongation at 
72qC for 10 minutes. Samples were then 
resolved using 1.5% Tris-acetate agarose gel 
electrophoresis and a product size of ~300 bp 
corresponding to the INBD promoter was 
observed. 
 
During the course of the study it became 
apparent that the GC-rich nature of the GDs 
promoter made its amplification by PCR 
difficult. Consequently, to analyse promoter 
occupancy in the GDs promoter (-837 to -618; 
48, 49) the following primers were used: GDs-
distal- VHQVH ¶-TTG GTT CGT GCT CGC 
CTC GC-¶ DQG *Ds-distal-3 anti-VHQVH ¶-
CAG TGA CGA CCC CTC GCA CG-¶7KH
following protocol was also utilised to 
facilitate PCR from the GC-rich -837 to -618 
region of the GDs promoter. Each 25µl 
reaction consisting of 5X Hercules buffer, 
25mM dNTPs, 0.25µl ChIP DNA, 100 pmol 
GDs-distal-3 sense, 100 pmol GDs-distal-3 
anti-sense, 0.25 Pl Hercules DNA polymerase 
(NB the manufacturer, Agilent, did not provide 
a value for the number of enzyme units/Pl) and 
1µl DMSO. Reactions conditions were: one 
cycle of denaturation at 98°C for 3 minutes, 38 
cycles of 98°C for 30 seconds, 61°C for 30 
seconds, 72°C for 30 seconds followed by a 
final elongation at 72qC for five minutes. 
Samples were then resolved using 1.5% Tris-
acetate agarose gel electrophoresis and a 
product size of ~219bp (-837 to -618 bp of the 
GDs promoter) were obtained. 
Band Intensity Analysis of Amplified, 
Immunoprecipitated DNA 
In this study, end-point PCR was used to give 
semi-quantitative data on enrichment levels of 
these respective transcription factors on each 
promoter. These analyses were undertaken 
using the SynGene GBox Chemi-16 gel 
documentation system to capture images. 
Subsequent band quantification was 
undertaken using GeneTools Version 4 
quantification software (SynGene, Cambridge 
U.K.). In all cases, the value ascribed to non-
specific binding of IgG was subtracted from 
the specific-binding value. That value was 
then expressed as a percentage of the input 
fraction; with the input fraction intensity being 
taken as 100%. Where statistically significant 
changes were observed, all appropriate ChIP 
gels are illustrated. 
 
Western Blot Analyses 
Western blot experiments were performed as 
detailed in Chapman et al. (22). Briefly, RelA 
expression was detected using anti-RelA C-
terminal antibody (Santa Cruz Biotechnology 
Inc. sc-372). The anti-acetyl-RelA anti-serum 
was obtained from Cell Signalling Technology 
(#3045) and detects transfected levels of RelA 
NF-NB only when residue Lys310 is 
acetylated. GE (Santa Cruz Biotechnology Inc. 
sc-378) was utilised to ensure equal well 
loading as detailed in Chapman et al. (22). 
After incubation with an appropriate 
secondary antiserum (125 ng goat-anti-rabbit-
HRP conjugates; #P0448; Dako), membranes 
were then washed in PBST and developed 
according to the EZ-ECL detection protocol 
supplied by Geneflow Ltd. (Staffordshire, 
U.K.). 
 
Myometrial Contractility 
The effects of TNF were tested in a model of 
myometrial contractility at 10 ng/ml and 30 
ng/ml. Experiments were carried out as 
described in Pearson et al. (58). Briefly, strips 
were mounted in vitro at 370C in a 
physiological salt solution aerated with 95% 
O2/5% CO2 and allowed to contract 
spontaneously. Following equilibration, 
separate concentration-response curves for 
both TSA and the NF-NB inhibitor, N4-[2-(4-
phenoxyphenyl)ethyl]-4,6-quinazolinediamine, 
(QNZ; 59) were generated.  The ability of 
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QNZ to modulate the contractile response was 
carried out by pre-incubating tissue ± 10 ng/ml 
or 30 ng/ml TNF for one hour prior to 
cumulative additions of TSA.  Data were 
analysed by calculating activity integrals for 
contractions over a 30 min period and 
concentration-effect curves fitted to a four 
parameter logistic equation (58).    
 
Statistical Analysis 
All experiments were performed a minimum 
of three times and results are expressed as the 
mean ± SEM (error bars). All data analyses 
were conducted on GraphPad Prism Version 
5.02 (GraphPad Software, San Diego, 
California). Data from transfection 
experiments and pharmacological studies were 
compared using one-way ANOVA and 
DQDO\VHG IXUWKHU XVLQJ 7XNH\¶V PXOtiple 
comparisons post-test. Comparison of data 
from two matched samples were compared 
using a paired, two-tailed t-test; p<0.05 was 
considered statistically significant. 
 
Results  
TNF Inhibits TSA-induced Relaxation in 
Isolated Strips of Human Myometrium: A 
Process Inhibited by Treatment with QNZ 
A number of pro-inflammatory cytokines, 
including TNF, are associated with the onset 
of both normal and preterm birth (23, 24). 
Together with data highlighting the reduction 
of GDs protein levels in term and pre-term 
labouring myometrium, we speculate that the 
localised inflammation within the myometrium 
is an important step in this transition from 
quiescence to contractility. Much of that work, 
however, has been conducted in primary cell 
monolayers. As such we wanted to determine 
how TSA, QNZ and TNF could influence 
contraction of isolated strips of human 
myometrium.  Firstly, cumulative addition of 
TSA was seen to relax spontaneously 
contracting, isolated myometrial strips (Fig. 
1A; red line; n = 6). Significantly, while TNF 
had little effect on TSA-induced myometrial 
relaxation at 10 ng/ml (Fig. 1A; blue line), it 
did, however, greatly reduce the TSA-induced 
relaxation at a concentration of 30 ng/ml (Fig. 
1A; green line). 
 
To support the notion that this contraction was 
mediated by the NF-NB family of transcription 
factors, the NF-NB inhibitor, QNZ, which is  
known to inhibit endogenous TNF synthesis 
(59), was also seen to inhibit myometrial 
contractions with an IC50 of 3.9x10-8M (n = 6) 
suggesting a role for NF-NB in this contractile 
response (Fig. 1B). 
Finally, pre-incubation of myometrial strips in 
50nM QNZ (a concentration close to the IC50) 
followed by addition of TSA also produced 
relaxation (Fig. 1C; green line; n = 6). In the 
presence of 30 ng/ml TNF and 50 nM QNZ a 
leftward shift in the concentration-response 
curve to TSA was seen (Fig. 1C; red line; n = 
6) supporting our view that myometrial 
relaxation induced by TSA can be modulated 
by TNF in a mechanism involving the NF-NB 
family of transcription factors. 
TNF Represses Expression of the GDs 
Promoter While Inducing NF-NB Activity A 
decline in both the level of mRNA and GDs 
protein within human myometrium has been 
shown to accompany the transition from 
quiescence to labour (22, 42). While the full 
details of this mechanism remain unclear, we 
have previously described the TNF-induced 
repression of a GDs-Luc reporter vector 
transfected into primary myometrial myocytes 
being mediated by the NF-NB RelA subunit 
competing for limiting quantities of the key 
transcription co-factor CBP (22).  
Consequently, control experiments were 
undertaken to determine that the myometrial 
cell cultures employed in this study behaved in 
a similar manner: briefly, TNFwas seen to 
repress the GDs-luc reporter (Fig. 2A) whilst 
inducing transcription from the NF-NB-
sensitive 3x-NB-luc vector (Fig. 2B). No 
activity was seen cells harbouring the ConA-
luc vector (which is not NF-NB sensitive) were 
exposed to TNF (Fig. 2C). Since we wished to 
investigate the regulation of the GDs promoter 
in the presence of activated NF-NB RelA, we 
confirmed, as expected, that TNF was 
inducing nuclear localisation of the RelA in 
primary myometrial myocytes (compare 
diffuse staining in un-stimulated or non-
specific IgG-stained cells (Fig. 2D; Left and 
Right panels) to TNF-stimulated cells (Fig. 
2D; Middle panel).  
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The -837 to -618 Region of the Endogenous 
GDs Promoter is Occupied by CREB, Egr-1 
and Sp1 and Also Recruits CBP The GDs 
promoter originally utilised in the GDs-luc 
vector represents the region from -790 to the 
Transcription Start Site (TSS; 45). Previous 
studies have concentrated on the more 
proximal aspects of that promoter sequence 
(45). Therefore, in this study, we wished to 
define how the more distal aspect of the GDs 
promoter, region -837 to -618, regulated 
expression (illustrated in Fig. 3A). 
 
The native GDs promoter is a GC-rich, TATA-
less regulatory region (48). Using the 
TransFac algorithm (49), we identified many 
putative transcription factor binding sites. 
Those of particular relevance to this study 
included Sp,  Egr and CREB families. Sp1 has 
been shown to play a pivotal role in regulating 
the expression of TATA-less GC-rich 
promoters through its ability to position RNA 
polymerase II at the appropriate initiator site 
(50, 51). Moreover, Sp1 is also thought to 
serve as an active boundary between non-
transcribed heterochromatin and 
transcriptional competent euchromatin (50). 
As such, it was decided to examine Sp1 in this 
context. Egr1 was chosen because it is a potent 
GC-rich binding zinc finger transcription 
factor. Moreover, it has been shown to 
compete with NF-NB RelA for DNA binding 
and also binds to CBP (28, 60). We decided to 
investigate CREB since it requires an 
interaction with CBP for full transactivation 
(61, 62) and, in terms of myometrial biology, 
both CREB and CBP have been demonstrated 
to have a pivotal role in GDs regulation (22, 
45, 52). Consequently, to determine if these 
factors were present on the endogenous GDs 
promoter we isolated primary myometrial 
smooth muscle cells as detailed above and 
cultured them until confluent. The ChIP assay 
was then utilised to determine if these factors 
were present on the distal GDs promoter 
fragment. Fig. 4A-4C demonstrates that 
CREB, Sp1 and Egr-1 occupied the -837 to-
618 aspect of the endogenous GDs promoter 
respectively. Positive controls for this 
experiment included occupation of the INBD 
promoter by RelA NF-NB (Fig. 4D). Other 
endogenous Sp and Egr family members were 
not detected in western analyses prior to the 
ChIP study (data not shown). 
 
Our previous work demonstrated that when 
CBP and the GDs-luc reporter vectors were co-
transfected into primary myometrial cells, 
expression of exogenous CBP was shown to 
enhance activity of the GDs promoter (Fig. 4A; 
Ref. 22). Factors such as CBP, however, do 
not have an intrinsic specific DNA binding 
domain but can still be recruited to a promoter 
through direct interactions with promoter-
bound heterologous factors (62). In the context 
of the GDs promoter, those factors identified in 
Fig. 3A-3C, namely CREB, Sp1 and Egr-1 
have all been documented to interact with CBP 
in various cells of various origins including the 
myometrium (60-62). Consequently, we 
wished to determine if CBP was also present 
within the -837 to -618 section of the native 
GDs promoter. To address this notion 
endogenous chromatin from primary 
myometrial myocytes was again subjected to 
the ChIP assay. Significantly, CBP was 
associated with this segment of the 
endogenous GDs promoter in native chromatin 
derived from myometrial myocytes (Fig. 5B; 
Upper Panel). To support this observation, we 
also examined the CXCL9 promoter which has 
previously also been shown to be a target of 
CBP (56). Again, in our studies we were also 
able to see CXCL9 promoter occupancy by 
CBP (Fig. 5B Lower panel). 
 
TNF Does Not Reduce GDs Promoter 
Occupancy by CREB, Sp1 or Egr-1 But 
Does Reduce Binding by CBP TNF has been 
shown to repress a GDs promoter construct 
transfected into myometrial cells (22). The 
factors involved in regulating the natural GDs 
promoter within its native context, however, 
have not been defined. In this present study, 
we employed the ChIP assay on chromatin 
extracted from TNF-stimulated primary 
myometrial myocytes, to determine whether 
there were any changes in the level of GDs 
promoter occupancy by the factors identified 
above, namely CREB, Egr-1 and Sp1. In the 
presence of TNF, we did not observe any 
noticeable change in the levels of CREB (Fig. 
6A), Egr-1 (Fig. 6B) or Sp1 (Fig. 6C) on the -
837 to -618 portion of the native GDs 
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promoter when the myometrial cells were 
exposed to TNF. 
 
As stated above, CBP is not thought to possess 
intrinsic DNA-binding ability instead relying 
on recruitment to the promoter through 
interactions with promoter-bond ancillary 
factors, including those identified herein. 
Expression of exogenous CBP alone was seen 
to enhance expression from the GDs-luc 
reporter vector (Fig. 5A; discussed above). 
Moreover, we previously demonstrated that 
expression of exogenous CBP could relieve 
TNF-induced repression of the GDs-luc 
promoter vector (22). That observation 
suggested that GDs repression was occurring 
because CBP was being removed or lost from 
the transcription complex based on the GDs 
promoter. To test this notion further, we 
undertook a series of ChIP analyses on TNF-
stimulated primary myometrial myocytes to 
determine if the level of CBP occupying the 
GDs promoter was reduced when cells were 
exposed to TNF. Fig. 6D clearly illustrates that 
the level of CBP present within the -837 to -
618 region of the endogenous GDs promoter is 
reduced approximately two-fold when 
myometrial myocytes were exposed to TNF. 
Again, to confirm that this system was 
working efficiently, TNF-induced occupancy 
of the INBD promoter by RelA served as the 
positive control (Fig. 6E; Upper panel). 
Moreover, we have previously demonstrated 
that RelA does not bind to the GDs promoter, 
consequently, that observation was utilised in 
this study to confirm that the effects observed 
herein were specific since, once again, there 
was no binding of RelA to the endogenous 
GDs promoter (Fig. 6E; Lower panel). 
 
GDs-luc Promoter Activity is Repressed by 
Histone Deacetylase-1 (HDAC-1) But 
Induced by the HDACi, TSA As discussed 
above, histone acetylation is generally 
associated with transcription of a given 
promoter while reciprocal histone 
deacetylation generally alters chromatin 
structure in a manner where it becomes 
refractory to transcription thereby silencing a 
given gene. In terms of myometrial function, 
there is increasing data that suggest 
deacetylation of myometrial genes may be of 
importance during quiescence. Indeed, both 
Phillips et al. (2005; 45) and Karolczak-
Bayatti et al. (2009; 47) have reported the 
binding of HDAC-1 to two other GC-rich 
control regions, namely the hCG/LH promoter 
and the PKA regulatory subunit RIID 
promoter. Consequently, we wished to test the 
notion that HDAC-1 could repress the function 
of the endogenous GDs-luc promoter 
construct. Importantly, when monolayers of 
primary myometrial smooth muscle cells co-
transfected with the GDs-luc and increasing 
amounts of HDAC-1, HDAC-1 caused a dose-
dependent repression of the GDs-luc promoter 
construct (Fig. 7A). Interestingly, the effect 
was observed with 500 ng of HDAC-1 plasmid 
DNA but reaching a maximal effect at the 
lower dose of 200 ng of HDAC-1 plasmid 
DNA. The reason for this is not clear but may 
reflect a phenomenon of promoter squelching 
when elevated levels of exogenous factors are 
introduced into the cell.  
 
To ensure that those observations where 
exogenous HDAC-1 repressed expression 
from the GDs-luc vector (Fig. 6A) were not 
merely due to promoter squelching, we also 
employed the ChIP assay to 
immunoprecipitate the endogenous GDs 
promoter using anti-HDAC-1 anti-serum. 
Cultures of primary myometrial cells were 
treated with TNF or not stimulated at all. As 
seen in Fig. 7B, TNF treatment causes an 
association of HDAC-1 with the endogenous 
GDs promoter supporting the notion that the 
HDAC-1 deacetylase is recruited to this region 
in the presence of inflammatory mediators.  
 
Since we observed that exogenous HDAC-1 
could repress activity of the GDs promoter, the 
obvious corollary was that the HDAC 
inhibitor, TSA, should induce activity of the 
GDs-luc construct. To test this notion, primary 
myometrial smooth muscle cells transfected 
with the GDs-luc vector were exposed to TSA 
(330nM). Fig. 7C clearly demonstrates that 
TSA can induce expression from the GDs-luc 
promoter construct. Moreover, the TNF-
induced repression of GDs could also be 
relieved when TSA was added to the cultures 
after TNF (Fig. 7C). Together, these data 
suggest the need for acetylation of this 
promoter and/or factors involved in regulating 
this region.  
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It has been reported that the NF-NB RelA 
subunit undergoes acetylation at key lysine 
residues prior to transactivation (63, 64). 
Moreover, HDAC inhibitors have been 
observed to facilitate this acetylation by 
reducing such deacetylase activity. As such, in 
terms of myometrial biology, where there is a 
thesis that HDAC inhibitors could serve a 
tocolytic (labour-stopping) function, we 
wished to determine whether TSA could 
facilitate acetylation, and hence activation of, 
RelA. To do this, primary myometrial 
myocytes were transfected with the 3x-NB-luc 
reporter and stimulated with TNF, TSA or 
DMSO vehicle. As can be seen in Fig. 7D, 
only TNF activated the NF-NB-sensitive 
reporter construct; neither TSA nor DMSO 
had any effect. Significantly, using western 
analysis with an antiserum specifically 
recognising acetylated RelA (acetyl-Lys 310), 
we did not see any changes in RelA 
acetylation status in the presence of TNF, TSA 
or DMSO (data not shown). We did, however, 
observe elevated nuclear localisation of RelA 
when cells were exposed to TSA (Fig. 7E; left 
panel) but this was still markedly below those 
levels seen for TNF  (Fig. 7E; right panel; 
same samples but reduced exposure time to 
illustrate TNF effect). Equal loading of 
samples was confirmed by probing for GE 
protein (Fig. 7E; 22). 
TNF Increases Histone H4K8 Acetylation 
on the GDs Promoter But Not That of 
Histone H3K9 It has been well documented 
that CBP is a potent histone acetyltransferase 
targeting a variety of intra-cellular factors 
including histone H3 and H4 (38). Acetylation 
of both H3 and H4 can be associated with both 
transcriptional activation or repression of a 
number of genes as they modify the inherent 
promoter architecture thereby enhancing the 
accessibility of the promoter to RNA 
polymerase II (65, 66 and references therein). 
At present, however, there are no data 
describing whether the GDs promoter is 
acetylated. Since we have identified CBP 
occupancy of the -837 to -618 region of the 
native GDs promoter (Fig. 5B) and that the 
level of CBP occupying that region of the GDs 
promoter is reduced in the presence of TNF 
(Fig. 4D) we wanted to determine (i) if the 
GDs promoter was acetylated and (ii) if there 
were changes in the acetylation status of either 
histone H3 or H4 within the GDs distal 
promoter fragment in primary myometrial 
myocytes upon exposure to TNF. Once again, 
myocytes were stimulated with TNFD for 24 
hours and further ChIP analyses performed for 
pan-acetylated lysine residues, acetylated 
Histone H3 or acetylated histone H4 within the 
endogenous distal GDs fragment. 
 
In our system, we did not observe any change 
in the levels of acetylated lysine within the -
837 to -618 GDs promoter region when cells 
were exposed to TNF (Fig. 8A). Moreover, we 
did not observe any change in the level of 
histone-H3K9 acetylation as judged by those 
ChIP analyses between controls and TNF-
stimulated cells (Fig. 8B). Significantly, 
however, exposure of primary myometrial 
smooth muscle cells to TNF was seen to 
induce an increase of approximately 2.5-fold 
in the GDs band intensity when ChIP was 
utilised for acetylated Histone H4K8 (Fig. 8C) 
suggesting this modification of the 
endogenous GDs promoter is elevated in the 
presence of TNF. 
 
Discussion 
TNF Overcomes TSA-induced Myometrial 
Relaxation The cumulative addition of TSA 
was seen to induce relaxation in isolated 
myometrial strips: an effect abolished by the 
addition 30 ng/ml TNF although TNF was not 
seen to induce myometrial contraction on its 
own. Whether contraction would be seen at 24 
hours (a similar time course utilised for the 
transfection and ChIP studies herein) remains 
unclear although certainly at 24 hours, tissue 
viability would be brought into question. 
Significantly, QNZ, the NF-NB inhibitor, 
prevented the TNF-induced modulation of 
TSA-mediated relaxation. This observation 
suggests two things; 1) the uterotonic actions 
of TNF have an NF-NB-regulated component 
to them; 2) the uterotonic effects of TNF can 
only occur once other factors, not identified in 
this study, are acetylated (TSA being an 
inhibitor of deacetylation). It remains unclear 
which NF-NB dimers are responsible for the 
TNF-induced effect. While QNZ is marketed 
as a specific NF-NB inhibitor, its molecular 
mechanism remains unclear. This is a salient 
point: essentially, for example, if QNZ 
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functions through inhibition of the INBD, then 
it would only serve to inhibit complexes 
regulated by that protein. There are certain 
NF-NB complexes, including p52 homodimers, 
p52:RelB heterodimers, that are not sensitive 
to INBD inhibition (23, 32) and would 
therefore not be targeted by QNZ. 
The GDs Promoter is Bound by a Number 
of Transcription factors Our current 
hypothesis suggests that acetylation of the GDs 
promoter by CBP is a pre-requisite for GDs 
expression in the human myometrium: a 
process which would facilitate uterine 
quiescence seen during pregnancy (22, 52). 
The corollary to this, therefore, is that 
inflammatory mediators, including TNF which 
we have previously shown to serve as a potent 
repressor of the GDs promoter (25), will exert 
their action through repression of the GDs 
promoter.  
In this study, to determine how TNF may 
repress expression from the GDs promoter, we 
have been able to demonstrate for the first time 
that the -837 to -618 region of the endogenous 
GDs promoter is occupied by the transcription 
factors CREB, Egr-1 and Sp1. We were unable 
to determine the exact loci of these sites in this 
study; as such the following may provide 
explanations for our observations. Firstly, the 
size of the chromatin fragments we obtained 
after sonication was ~500bp (data not shown), 
consequently, we cannot rule out that the 
chromatin enrichment we observed in our 
ChIP assays may also include sequences 
located both more proximally or distally to the 
-837 to -618 GDs fragment studied herein. For 
example, the ChIP is still specific for CREB, 
Egr-1 and Sp1 etc. and the primers remain 
specific for the appropriate sequences flanking 
the -837 to -618 region, but if the specific 
enriched fragment contains both a more 
proximal or distal transcription factor binding 
site and the site of primer recognition, then 
such a result suggests direct occupancy of the 
region under study. 
 
Secondly, to put this into context of 
nucleosomes, we have investigated a fragment 
of 219 bp; essentially this represents one 
complete nucleosomal particle with an extra 
69 bp of DNA. We cannot, therefore, be 
certain that the effects we have observed occur 
throughout the entire regulatory locus of the 
GDs region or whether they are restricted to 
this particular nucleosomal region. Such 
explanations, however, does not detract from 
our findings because it still supports the thesis 
that these factors are binding and regulating 
the GDs promoter. 
 
We also demonstrated that exogenous histone 
deacetylase activity, namely HDAC-1, could 
repress the GDs-luc promoter while TNF 
stimulation induced occupancy of the GDs -
837 to -618 fragment by endogenous HDAC-
1. Furthermore, the HDAC inhibitor, TSA, had 
the opposite effect and induced GDs promoter 
activity. Together, these observations support 
the view that deacetylation of the GDs 
promoter is an important regulatory 
mechanism. At present, however, we were 
unable to fully define whether the 
deacetylation was specific to nucleosomal 
histones, or whether the deacetylation was 
more global; inducing its effects through 
promoter-bound ancillary factors other than 
histones. 
H4K8 Acetylation and GDs Promoter 
Repression The obvious question posed by 
our data is that if deacetylation is required to 
reduce or silence GDs expression, why should 
an increased recovery of acetylated histone H4 
be observed in the distal GDs fragment in the 
presence of TNF. Firstly, in terms of an 
explanation for this observation of increased 
H4K8 acetylation with TNFD, is that 
acetylation at H4K8 is required to stabilise the 
interaction between DNA and the repressor 
element 1-silencing (REST) protein (reviewed 
in Ooi and Wood, 2007; 65). This mechanism 
requires that the interaction between REST 
and DNA is stabilised by the binding of the 
ATP-dependent chromatin-remodelling 
enzyme, BRG1 (which forms part of the REST 
complex) to H4K8 (65). In doing so the REST 
complex can subsequently serve as a platform 
for other transcriptional repressors, including 
the HDAC-1 and -2-containing complex of 
mSin3 (65). As such, increased H4K8 
acetylation as seen in our data, induced by 
CBP prior to removal from the GDs promoter 
region, would facilitate the binding and 
stabilisation of the REST:mSin3 complex to 
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the distal GDs fragment and induce repression 
of that promoter. Further work is needed to 
test this hypothesis because there is evidence 
that mSin3-associated HDAC-1 can 
deacetylate histone H3K9; our data described 
herein did not see such H3K9 deacetylation in 
the presence of TNF. 
 
In terms of interaction with those factors in the 
distal GDs promoter, REST has been shown to 
bind Sp1 and Egr-1. In both studies, 
bidirectional regulation of the specific target 
genes were noted; i.e. Sp1 could activate 
expression of sodium channels; while Egr-1 
stimulated expression of the Cav3.2 T-type 
Ca2+ channel. In the presence of REST both 
these effects were repressed (66, 67). As such, 
we speculate a similar mechanism may be 
occurring to govern expression of the GDs 
GTP binding protein.  
 
Influence of Non-genomic Protein 
Acetylation Previous work has also 
demonstrated a key role for lysine acetylation 
of Hsp20 (68). This post-translational 
modification was seen to govern the 
interaction between Hsp20 and cofilin, Indeed, 
inhibitors of the non-nuclear lysine 
deacetylase (KDAC) KDAC8 modified Hsp20 
acetylation profile in such a manner that 
myometrial contractility was subsequently 
inhibited.  
 
At present, the exact mechanism by which 
TNF influences acetylation and GDs 
expression is unclear. TNF is a potent inducer 
of NF-NB activity; indeed, RelA NF-NB is 
documented to undergo CBP-mediated 
acetylation at Lys218, 221 and 310 (Chen et 
al. 2001).  Moreover, Dai et al. (2005) 
subsequently reported that newer HDAC 
inhibitors including SAHA and MS-275 
induced acetylation and nuclear localisation of 
RelA. That group suggested that this was 
necessary for NF-NB-induced anti-apoptotic 
effects in certain leukaemia cells (Dai et al., 
2005; 64). We did not observe TSA-induced 
acetylation of RelA in this study although the 
antiserum used was specified by the 
manufacturer to only be effective against 
transfected RelA not the endogenous protein: 
this may account for our lack of data in that 
experiment. We did, however, also note that 
TSA stimulation of myometrial cells caused an 
increase in RelA nuclear localisation without 
activating the NF-NB-sensitive 3x-NB-luc 
reporter. The significance of that observation 
remains unclear at present but may be due to a 
delay in INBD re-synthesis similar to that seen 
for pervanadate-induced NF-NB activation 
(69). Moreover, it would also suggest that, in 
the context of myometrial function, a cautious 
approach to employing HDAC inhibitors as 
tocolytic (labour-stopping) drugs should be 
employed.  Briefly, there is growing body of 
literature interested in understanding whether 
HDAC inhibitors may be of use clinically as 
tocolytic drugs (17, 68, 70). While such 
studies do present convincing effects that 
HDACi inhibitors such as TSA exert robust 
pro-relaxant effects on isolated strips of human 
myometrium (17, 68, 70; Fig. 1 this study), we 
must, however, also consider potential 
unwanted effects including acetylation and 
subsequent activation of non-chromatin based 
factors that could also promote labour ± i.e. 
NF-NB RelA such as that described by Chen et 
al. (63). Indeed, our data demonstrate that 
TNF can overcome TSA-mediated myometrial 
relaxation. If HDAC inhibitors are having a 
positive effect on the activity of NF-NB, 
utilising them in the clinical setting may only 
serve to exacerbate those premature 
myometrial contractions that the drug was 
given to prevent. 
 
Conclusions In conclusion, our data 
demonstrate that the HDAC inhibitor, TSA 
induces relaxation in isolated strips of human 
myometrium; an effect that can be overcome 
by stimulation of such tissues with TNF. 
While TNF itself did not induce contraction, 
the NF-NB inhibitor, QNZ did repress the TNF 
effect while also sensitising the tissue to TSA 
implying that the NF-NB family serve an 
important function in this modulatory role. 
Subsequent studies into the regulation of the 
pro-quiescent factor, the GDs GTP binding 
protein, demonstrated that the -837 to -618 
region of the endogenous GDs promoter is 
occupied by CREB, Egr-1 and Sp1 
transcription factors. Moreover, CBP is also 
found associated with this region: we believe 
CBP is required to acetylate the GDs promoter 
leading to GDs expression. In the presence of 
TNF, while there is no discernible change in 
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the level of CREB, Sp1 or Egr-1 bound to the 
GDs promoter, there was significant reduction 
in the amount of CBP: an observation that was 
supported by increased levels of HDAC-1 and 
elevated H4K8 acetylation. We were also able 
to show that exogenous HDAC enzymes, 
namely HDAC-1 could repress the GDs-luc 
construct while reciprocal activation was seen 
with exogenous CBP or the HDACi, TSA.  
Taken together, our data suggest that 
expression from the GDs promoter is, in part, 
governed by protein acetylation.  
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Figure Legends 
Fig. 1: TNF, TSA and QNZ all Effect Myometrial Contraction. Isolated myometrial strips were 
prepared as described in Materials and methods. (A) Myometrial tissue strips (n = 6 for each 
observation) were incubated in either 10 ng/ml or 30 ng/ml TNF for 1 hour followed by the 
cumulative addition of 10-9-10-5M TSA to the bath. Data were analysed using an unpaired, two-tailed 
t-test and results are expressed as the mean r S.E.M. (error bars); p<0.05 was considered statistically 
significant. Control strips were incubated with vehicle and showed no significant change in 
contractility with time. TSA alone caused a concentration-dependent relaxation of spontaneous 
myometrial contractions which was inhibited in the presence of 30 ng/ml TNF but unaffected by 10 
ng/ml.  (B) QNZ inhibited myometrial contractility in a concentration-dependent manner with IC50 
3.9x 10-8M. (C) Cumulative addition of TSA to myometrial tissues pre-incubated with QNZ (50 nM) 
and TNF (30 ng/ml) produced a leftward shift in the response compared with QNZ alone. 
Fig 2: TNF Represses GDs Expression Whilst Inducing NF-NB Activity in Primary Myometrial 
Myocytes. Primary myometrial cultures were transfected with 200 ng of either (A) GDs-luc, (B) 3x-
NB-ConA-luc (NF-NB-responsive) or (C) 'NB-ConA-luc (NF-NB unresponsive). After 24 hours cells 
were stimulated with TNF (10 ng/ml) for 24 hours. Promoter activity was quantified using a Berthold 
Sirius tube luminometer. All experiments were performed three times in triplicate. Data were analysed 
using an unpaired, two-tailed t-test and results are expressed as the mean r S.E.M. (error bars); 
p<0.05 was considered statistically significant. As expected, TNF repressed GDs expression (A; p = 
0.002) and activated NF-NB (B; p = 0.036). No NF-NB activity was observed in a control reporter 
lacking NB sites (C). Immunostaining was used to demonstrate TNF-mediated induction of RelA 
nuclear localisation in primary myometrial myocytes (D; white arrows. Compare Middle Panel; TNF-
stimulated with Left Panel; un-stimulated and Right Panel; negative control; scale bar = 100Pm).  
 
Figure 3: Schematic Illustration of the GDs Promoter Highlighting the -837 to -618 Region. The 
GDs promoter originally utilised in the GDs-luc vector represents the -790 to the Transcription Start 
Site (TSS; A). In terms of experimental analyses, this study focussed on the more distal aspect of this 
promoter (-837 to -618; B) and this was the target for use in the ChIP assays herein unless stated 
otherwise. 
Fig. 4: The -837 to -618 GDs Promoter Fragment is Occupied by CREB, Sp1 and Egr1. Primary 
cultures of myometrial cells were subjected to the ChIP assay. It was clear that CREB (A), Sp1 (B) 
and Egr-1 (C) occupied the endogenous distal GDs promoter. TNF-induced RelA occupancy of the 
INBD promoter illustrated the ChIP assay was functioning correctly (D). 
Fig. 5: Exogenous CBP Induces GDs-luc Activity While Endogenous CBP is Recruited to the -
837 to -618 Region of the Native GDs Promoter. Primary myometrial cultures were transfected with 
200 ng of GDs-luc and 200 ng, 400 ng or 500 ng of CBP. Cells were harvested after 24 hours and 
luciferase activity was quantitated. All experiments were performed three times in triplicate. Data 
were compared using one-ZD\$129$DQGDQDO\VHGIXUWKHUXVLQJ7XNH\¶VPXOWLSOHFRPSDULVRQVWHVW 
and results are expressed as the mean r S.E.M. (error bars); p<0.05 was considered statistically 
significant. CBP strongly induced GDs expression at all doses (A; p = 0.001). Employing the ChIP 
assay on cultures of primary myometrial myocytes, it was shown that endogenous CBP was also 
observed to occupy the endogenous GDs promoter (B; Upper Panel). CBP occupancy of the CXCL 
promoter served as the positive control (B; Lower Panel).  
Fig. 6: TNF Does Not Reduce GDs Promoter Occupancy by CREB, Sp1 or Egr-1 But Does 
Reduce Binding by CBP. Primary cultures of myometrial cells were stimulated with TNF (10 ng/ml) 
for 24 hours and subjected to the ChIP assay with antisera depicted above. All experiments were 
performed three times and data were compared using a paired, two-tailed t-test and results are 
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expressed as the mean r S.E.M. (error bars); again p<0.05 was considered statistically significant. 
TNF was not seen to significantly alter the amount of bound CREB (A), Sp1 (B) and Egr-1 (C). TNF 
did, however, significantly reduce the amount of CBP present within the GDs promoter (D; p = 
0.0128). As expected, TNF induced RelA occupancy of the INBD promoter (E; upper panel) 
although, as expected, there was no binding of RelA to the endogenous GDs promoter (E; Lower 
Panel).  
Fig. 7: GDs-luc Activity is Repressed by HDAC-1 But Induced by TSA. Primary myometrial 
cultures were transfected with 200 ng of GDs-luc and 200 ng, 400 ng or 500 ng of HDAC-1. Cells 
were harvested after 24 hours and luciferase activity was quantitated. HDAC-1 strongly repressed 
GDs expression at all doses, and maximally at 200 ng (A; p = 0.0047). Primary cultures of myometrial 
cells were stimulated with TNF (10 ng/ml) for 24 hours and subjected to the ChIP assay with anti-
HDAC-1 antiserum. Data were compared using a paired, two-tailed t-test and results are expressed as 
the mean r S.E.M. (error bars); again p<0.05 was considered statistically significant. TNF was seen 
to induce an increase in HDAC-1 occupancy of the endogenous GDs promoter (B; p = 0.047). Primary 
myometrial cultures were transfected with 200 ng of GDs-luc and then 24 hours later stimulated with 
TNF (10 ng/ml) for 24 hours. TSA (330nM) was then added to the culture medium for 24 hours. 
Cells were harvested and luciferase activity was quantitated. Data were compared using one-way 
$129$DQGDQDO\VHGIXUWKHUXVLQJ7XNH\¶VPXOWLSOHFRPSDULVRQVWHVW and results are expressed as 
the mean r S.E.M. (error bars); p<0.05 was considered statistically significant. TSA was seen to 
activate GDs-luc activity and overcome TNF-induced GDs-luc repression (C; p<0.001). Primary 
myometrial cultures were transfected with 200 ng of GDs-luc and then 24 hours later stimulated with 
either TNF (10 ng/ml) for 24 hours, TSA (330nM) for 24 hours, or TNF and then TSA. Only TNF 
activated the NF-NB-sensitive 3x-NB-luc reporter (D; p = 0.0001). Cultures of primary myometrial 
cells were stimulated with either TNF (10 ng/ml) for 24 hours; TSA (330nM) for 24 hours or TNF 
and then TSA. Nuclear extracts were subsequently prepared and probed for the expression of acetyl-
RelA (K310) and total RelA. No acetyl-RelA was detected in response to any stimulant (not shown). 
TSA, however, induced significant RelA nuclear localisation but this remained less than that seen 
with TNF (E; upper panels). Equal loading was confirmed by blotting for GE (E; lower panel). All 
experiments were performed three times and results are expressed as the mean ± SEM. 
Fig. 8: TNF Does Not Alter Global Levels of Histone Acetylation or Histone-H3K9 Acetylation 
But Does Increase Histone-H4K8 Acetylation in the -837 to -618 GDs Promoter Fragment. 
Primary cultures of myometrial cells were stimulated with TNF (10 ng/ml) for 24 hours and subjected 
to the ChIP assay with antisera depicted above. Data were compared using a paired, two-tailed t-test; 
again p<0.05 was considered statistically significant. All experiments were performed three times and 
results are expressed as the mean ± S.E.M. (error bars). TNF did not alter the amount of global levels 
of acetylated lysine-containing proteins (A) or acetylated histone-H3K9 (B) within the endogenous 
GDs promoter but it induced an approximately threefold increase in acetylated histone-H4K8 levels in 
the endogenous -837 to -618 GDs promoter region (C). 
 








